FDA grants BTD for Venclexta in combination with azacitidine to treat patients with myelodysplastic…
Every year, approximately 10,000 people are diagnosed with myelodysplastic syndromes (MDS) in the US, and there remains a high…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Venclexta
Genentech announces full FDA approval for Venclexta combinations for acute myeloid leukaemia
The approval is primarily based on the results of two Phase III studies, VIALE-A and VIALE-C
Acute myeloid leukaemia market to reach $5.1 billion by 2029: GlobalData
This growth will be driven by label expansions of the already successful drugs Venclexta, Tibsovo, Idhifa and Xospata, as well as…
AbbVie completes acquisition of Allergan
The transaction significantly expands and diversifies AbbVie’s revenue base and complements existing leadership positions in…